138 related articles for article (PubMed ID: 27197195)
1. mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.
Li J; Shin S; Sun Y; Yoon SO; Li C; Zhang E; Yu J; Zhang J; Blenis J
Cancer Res; 2016 Aug; 76(16):4816-27. PubMed ID: 27197195
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.
Li J; Csibi A; Yang S; Hoffman GR; Li C; Zhang E; Yu JJ; Blenis J
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E21-9. PubMed ID: 25524627
[TBL] [Abstract][Full Text] [Related]
3. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
4. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
6. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
8. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
[TBL] [Abstract][Full Text] [Related]
9. p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.
Lam HC; Baglini CV; Lope AL; Parkhitko AA; Liu HJ; Alesi N; Malinowska IA; Ebrahimi-Fakhari D; Saffari A; Yu JJ; Pereira A; Khabibullin D; Ogorek B; Nijmeh J; Kavanagh T; Handen A; Chan SY; Asara JM; Oldham WM; Diaz-Meco MT; Moscat J; Sahin M; Priolo C; Henske EP
Cancer Res; 2017 Jun; 77(12):3255-3267. PubMed ID: 28512249
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.
Yoon S; Kim JH; Kim SE; Kim C; Tran PT; Ann J; Koh Y; Jang J; Kim S; Moon HS; Kim WK; Lee S; Lee J; Kim S; Lee J
J Med Chem; 2016 Nov; 59(22):10322-10328. PubMed ID: 27933890
[TBL] [Abstract][Full Text] [Related]
11. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Sun D; Liu H; Dai X; Zheng X; Yan J; Wei R; Fu X; Huang M; Shen A; Huang X; Ding J; Geng M
Cancer Lett; 2017 Oct; 406():105-115. PubMed ID: 28687354
[TBL] [Abstract][Full Text] [Related]
12. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
13. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
14. Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide.
Parkhitko AA; Priolo C; Coloff JL; Yun J; Wu JJ; Mizumura K; Xu W; Malinowska IA; Yu J; Kwiatkowski DJ; Locasale JW; Asara JM; Choi AM; Finkel T; Henske EP
Mol Cancer Res; 2014 Jan; 12(1):48-57. PubMed ID: 24296756
[TBL] [Abstract][Full Text] [Related]
15. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.
Dunlop EA; Johnson CE; Wiltshire M; Errington RJ; Tee AR
Oncotarget; 2017 Jul; 8(30):48711-48724. PubMed ID: 28415776
[TBL] [Abstract][Full Text] [Related]
18. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis.
Priolo C; Ricoult SJ; Khabibullin D; Filippakis H; Yu J; Manning BD; Clish C; Henske EP
Am J Respir Cell Mol Biol; 2015 Jul; 53(1):33-41. PubMed ID: 25780943
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
[TBL] [Abstract][Full Text] [Related]
20. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
